On the afternoon of March 17, the State Council’s Joint Prevention and Control Mechanism held a press conference to introduce the latest situation in the research and development of drugs, vaccines and testing reagents. In terms of the latest progress in the research and development of drugs for the treatment of new crown pneumonia, Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, introduced that the scientific research and study group further strengthened the support and service for front-line clinical treatment. For the blockage of the transformation of light and ordinary type to heavy type, it focuses on promoting chloroquine phosphate, favipiravir and traditional Chinese medicine, and for the rescue and treatment of heavy and critical patients, it focuses on promoting the clinical application of recovery plasma, tolizumab, stem cells and artificial liver, and all of them have made good progress so far. Among them, Fapiravir has completed clinical studies and shown good clinical efficacy. In terms of safety, Fapiravir has been approved for marketing in Japan in 2014, and no significant adverse reactions have been seen since its launch. In the clinical study for the treatment of neocoronitis, no significant adverse reactions were found. In terms of effectiveness, in the study of the effectiveness and safety of famipiravir combined with interferon in the treatment of neocoronaryngitis carried out by the Third People’s Hospital of Shenzhen City, 80 patients were enrolled, of which 35 cases were in the famipiravir group and 45 cases were in the control group. The results of the study showed that in terms of viral nucleic acid conversion, the median value of conversion time was significantly shorter in the treated patients in the famipiravir treatment group compared with the control group, which was 4 days and 11 days, respectively, with a significant difference. In terms of chest imaging improvement, the improvement rates were 91.43% and 62.22%, respectively, compared with the control group. Zhongnan Hospital of Wuhan University led a multi-center, randomized, open, positive parallel-controlled clinical study of Fapiravir in the treatment of neocoronaryngitis, which has completed the enrollment and clinical treatment observation of 120 cases each. The results of the clinical study showed that the efficacy of the trial group in treating neocoronary pneumonia was significantly better than that of the control group. In terms of the primary endpoint evaluation index, the clinical recovery rate of general-type patients at the end of treatment was significantly better in the experimental group than in the control group, with 71.43% and 55.86%, respectively. In terms of secondary endpoints, the test group was significantly better than the control group in terms of time to remission of fever, with a mean time to remission of fever of 2.5 days and 4.2 days, respectively. The test group was significantly better than the control group in the time to cough relief, with a mean time to cough relief of 4.57 days and 5.98 days, respectively, and the rate of adjuvant oxygen therapy or noninvasive mechanical ventilation during the treatment period of patients with common type was significantly lower in the test group than in the control group, with a mean time to cough relief of 8.16% and 17.12%, respectively. All of the above evaluation indicators were statistically different between the two groups. In terms of accessibility, in February this year, domestic enterprises have obtained drug registration approvals from the State Drug Administration and realized mass production, so the supply of clinical drugs is guaranteed. In view of the good safety, clear efficacy and accessibility of Fapiravir, after the scientific research group has organized experts to fully demonstrate, it has been formally recommended to the medical treatment group, and suggested to be included in the diagnosis and treatment plan as soon as possible. The next step is that the research team will further promote the application of the research results in Wuhan, and launch a Chinese program for drug treatment in response to the current international outbreak situation. Source: Beijing Daily